Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity

1975 • 1,308 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

Age Influence on the Immune System

1980 • 703 citations

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1981 • 703 citations

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

1986 • 698 citations

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

1986 • 534 citations

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

1981 • 516 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1985 • 376 citations

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

1984 • 299 citations

Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced Cancer

1987 • 170 citations

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.

1986 • 149 citations

Methods for preparation of media, supplements, and substrata for serum-free animal cell culture

1984 • 146 citations

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1

1988 • 139 citations

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

1985 • 136 citations

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

1988 • 131 citations

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1985 • 130 citations

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.

1984 • 112 citations

Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors

1989 • 101 citations

B16 Murine Melanoma and Aging: Slower Growth and Longer Survival in Old Mice23

1984 • 96 citations

Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.

1987 • 96 citations

Systemic administration of recombinant human interleukin-2 in mice.

1984 • 85 citations

Studies of murine large granular lymphocytes. II. Tissue, strain, and age distributions of LGL and LAL.

1982 • 84 citations

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1986 • 68 citations

Local and systemic effects during interleukin-2 therapy of mouse mammary tumors.

1987 • 60 citations

Why Tumors Grow More Slowly in Old People<xref ref-type="fn" rid="FN3">3</xref>

1986 • 43 citations

Role of the thymus and T-cells in slow growth of B16 melanoma in old mice.

1987 • 40 citations

Transfer of age-associated restrained tumor growth in mice by old-to-young bone marrow transplantation.

1984 • 37 citations

Immunologic enhancement of b16 melanoma growth

1988 • 13 citations

Summary: potential of interleukin-2 for the therapy of cancer.

1984 • 11 citations

Phase 1 clinical evaluation of recombinant interleukin-2.

1987 • 7 citations

Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo.

1984 • 7 citations